The patent, which was first filed in October of 2014, is an important step for CortControl.
CortControl’s Glutrasol™ IF fertility food is being clinically tested to enhance traditional infertility protocols and provide a low-cost consideration for improved efficacy. This fertility-enhancement food is consumed by subjects seven or more days before planned conception.
CortControl is the sister company to Ramaekers Nutrition. Founded in 1969 by Dr. Joseph Ramaekers, Ramaekers Nutrition has been developing patented natural veterinary products to educate immune cells and enhance their function. CortControl is leveraging 40 years of studies and science developed by Ramaekers Nutrition and is applying efficacy formulation experience to the human arena with this human fertility enhancement treatment.
Glutrasol IF offers two distinctive benefits for both fertility specialists and patients. First, because Glutrasol IF is a medical food ingested just like other foods, it is a non-invasive form of treatment. And second, it is far less expensive than in-vitro fertilization and other fertility treatments. “For these reasons, and because of its proven effectiveness with livestock, we believe that Glutrasol IF can be a sensible, low-cost initial treatment that effectively addresses infertility for many couples before specialists turn to more invasive and costly approaches,” said Jim Daniels, founder and CEO of CortControl.
For pharmaceutical companies and others interested in partnering with CortControl in the production, marketing, and distribution of Glutrasol™ IF, an enormous opportunity also exists. According to the Mayo Clinic, between 10% and 15% of all couples of childbearing age have difficulty either conceiving or taking a pregnancy through to term. In the U.S. alone, this represents tens of millions of couples—many of them potential Glutrasol™ IF users.
In addition to the company’s fertility treatment food, CortControl has patents pending for vaccine enhancement and more patents planned for other treatment protocols where diminished immune function has a direct correlation to treatment efficacy.
“Immune enhancement is a pivotal element for increasing the efficacy of numerous treatment protocols, so the positive impact on patients undergoing those protocols is very real,” Daniels said. “We are actively working in other arenas to bring these solutions to market.”
CortControl develops market-ready, patent-protected medical foods for manufacture and distribution. CortControl’s Glutrasol™ family of products, when combined with other specific medical protocols, such as vaccine regimes, infertility treatments and others, work to boost immune function to dramatically improve the efficacy of those protocols. CortControl is committed to advancing global health by sharing emerging technologies with donors, tech researchers, manufacturers and delivery organizations. Learn more at http://www.cortcontrol.com/infertility.